MX2024006556A - Inhibidores de peptido del receptor de interleucina-23. - Google Patents

Inhibidores de peptido del receptor de interleucina-23.

Info

Publication number
MX2024006556A
MX2024006556A MX2024006556A MX2024006556A MX2024006556A MX 2024006556 A MX2024006556 A MX 2024006556A MX 2024006556 A MX2024006556 A MX 2024006556A MX 2024006556 A MX2024006556 A MX 2024006556A MX 2024006556 A MX2024006556 A MX 2024006556A
Authority
MX
Mexico
Prior art keywords
interleukin
peptide inhibitors
receptor peptide
compounds
diseases
Prior art date
Application number
MX2024006556A
Other languages
English (en)
Spanish (es)
Inventor
Jesper Mosolff Mathiesen
Henrik Fischer Munch
Rasmus Leth
Niels Bjerre Holm
Bjarne Due Larsen
Octav Caldararu
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Publication of MX2024006556A publication Critical patent/MX2024006556A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024006556A 2021-12-01 2022-12-01 Inhibidores de peptido del receptor de interleucina-23. MX2024006556A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21211815 2021-12-01
PCT/EP2022/084077 WO2023099669A1 (en) 2021-12-01 2022-12-01 Peptide inhibitors of interleukin-23 receptor

Publications (1)

Publication Number Publication Date
MX2024006556A true MX2024006556A (es) 2024-06-12

Family

ID=78821013

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024006556A MX2024006556A (es) 2021-12-01 2022-12-01 Inhibidores de peptido del receptor de interleucina-23.

Country Status (12)

Country Link
US (1) US20250154198A1 (cg-RX-API-DMAC7.html)
EP (1) EP4440592A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024543204A (cg-RX-API-DMAC7.html)
KR (1) KR20240111800A (cg-RX-API-DMAC7.html)
CN (1) CN118354781A (cg-RX-API-DMAC7.html)
AU (1) AU2022402440A1 (cg-RX-API-DMAC7.html)
CA (1) CA3240982A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001598A1 (cg-RX-API-DMAC7.html)
IL (1) IL313185A (cg-RX-API-DMAC7.html)
MX (1) MX2024006556A (cg-RX-API-DMAC7.html)
TW (1) TW202332682A (cg-RX-API-DMAC7.html)
WO (1) WO2023099669A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4471048A1 (en) * 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
EP4471049A1 (en) * 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
CN121794283A (zh) * 2023-09-08 2026-04-03 赛诺菲 作为选择性il-23受体抑制剂的新型肽
WO2026013260A1 (en) 2024-07-12 2026-01-15 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2026026815A1 (zh) * 2024-07-30 2026-02-05 西藏海思科制药有限公司 白介素-23受体的肽抑制剂及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
SG10201810154WA (en) 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
HK1257747A1 (zh) 2015-07-15 2019-10-25 Protagonist Therapeutics Inc. 白细胞介素-23受体的肽抑制剂以及其治疗炎症性疾病的用途
WO2018022937A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
US20200064357A1 (en) * 2016-11-09 2020-02-27 Protagonist Therapeutics, Inc. Methods for determining and monitoring gastrointestinal inflammation
JP2020505352A (ja) 2017-01-18 2020-02-20 プロタゴニスト セラピューティクス, インコーポレイテッド インターロイキン−23受容体のペプチド阻害剤および炎症性疾患を治療するためのそれらの使用
CA3104418A1 (en) 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2020311395A1 (en) 2019-07-10 2022-02-03 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
MX2022008740A (es) * 2020-01-15 2022-09-23 Janssen Biotech Inc Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
WO2021146458A1 (en) 2020-01-15 2021-07-22 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
SMT202500254T1 (it) 2020-01-15 2025-09-12 Janssen Biotech Inc Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie

Also Published As

Publication number Publication date
AU2022402440A1 (en) 2024-05-30
CA3240982A1 (en) 2023-06-08
IL313185A (en) 2024-07-01
JP2024543204A (ja) 2024-11-19
EP4440592A1 (en) 2024-10-09
CN118354781A (zh) 2024-07-16
KR20240111800A (ko) 2024-07-17
CL2024001598A1 (es) 2024-11-15
TW202332682A (zh) 2023-08-16
WO2023099669A1 (en) 2023-06-08
US20250154198A1 (en) 2025-05-15

Similar Documents

Publication Publication Date Title
CL2024001598A1 (es) Inhibidores de péptido del receptor de interleucina-23
MX2022008741A (es) Inhibidores de peptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
MX2022000397A (es) Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
MA58170B1 (fr) Dérivés carboxy avec des proprietes anti-inflammatoires
MX2022008740A (es) Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
EA201890618A1 (ru) Способы и композиции для лечения состояний, ассоциированных с аномальными воспалительными ответами
JOP20230186A1 (ar) أجسام مضادة لـ cd30l واستخداماتها
EP3999121A4 (en) TREATMENT/PREVENTION OF DISEASE BY INHIBITION OF LING COMPLEX
EP3601531C0 (en) TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH LIVE BIOTHERAPEUTICS
MA31668B1 (fr) Polypeptides, domaines variables d'anticorps et antagonistes
MA31767B1 (fr) Composes organiques et leurs utilisations
EA200971130A1 (ru) Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
MA50013B1 (fr) Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton
NO20071343L (no) Substituerte fenylaminotiazoler og anvendelse derav
WO2005072113A3 (en) Compositions and methods of treatment for inflammatory diseases
EP3737376A4 (en) SELECTIVE HISTONE ACETYLASE INHIBITORS FOR THE TREATMENT OF HUMAN DISEASES
MX2022011697A (es) Inhibidores de ciclofilina y usos de los mismos.
EA202190952A1 (ru) Соединения и композиции для лечения патологических состояний, связанных с активностью рецептора apj
EA202190310A1 (ru) Белок для лечения воспалительных заболеваний
MX2022008265A (es) Compuestos y metodos para el tratamiento del dolor visceral.
PH12020500204A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic disease
EP3440045A4 (en) PREVENTING, TREATING AND REVERSING DISEASES USING THERAPEUTICALLY ACTIVE AMOUNTS OF DICARBONIC ACID COMPOUNDS
EA202190452A1 (ru) Ингибиторы cdk8/19
WO2022093552A3 (en) Rev-erb agonists
EP3806865A4 (en) MODIFIED TETRACYCLINE FOR THE TREATMENT OF ALCOHOL ABUSE, PAIN AND OTHER DISEASES WITH POTENTIAL INFLAMMATORY PROCESSES